David Kallend - LIB Therapeutics and DalCor Pharmaceuticals Founder Kallend Pharmaconsulting

基本信息

Career Trajectory

Bio

David Kallend is currently Chief Scientific Officer and Chief Medical Officer of DalCor Pharmaceuticals and Chief Medical Officer of LIB Therapeutics. David does research in lipidology, diabetology, Internal Medicine (General Medicine), imaging and Cardiology. His current projects are dalcetrapib and lerodalcibep (LIB003).

Research Interests

Papers共 155 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

RISK SCORE FOR FUTURE MYOCARDIAL INFARCTION AFTER AN ACUTE CORONARY SYNDROME AND PHARMACOGENETIC RESPONSE TO DALCETRAPIB

Jean Claude Tardif,Marc A. Pfeffer,Simon Kouz,Wolfgang Koenig, Aldo Pietro Maggioni,John J.V. McMurray, David D. Waters,Jean C. Gregoire,Philippe L. L’Allier, Johan Wouter Jukema,Harvey D. White,Therese Heinonen,David Kallend, Fouzia Laghrissi-Thode,Annik Fortier,Marie-Claude Guertin,Marie-Pierre Dube

Journal of the American College of Cardiologyno. 12 (2025): 1778

Cited0Views0Bibtex

Lerodalcibep and Evolocumab for the Treatment of Homozygous Familial Hypercholesterolaemia with PCSK9 Inhibition (Liberate-Hofh): a Phase 3, Randomised, Open-Label, Crossover, Non-Inferiority Trial

Frederick J Raal,Vimal Mehta,Meral Kayikcioglu,Dirk Blom,Preeti Gupta,Avishay Elis,Traci Turner, Chris Daniels, Jeffrey Vest,Tracy Mitchell,Kate Caldwell,El Mustapha Bahassi,David Kallend,Evan A Stein

The Lancet Diabetes & Endocrinology (2025)

Cited0Views0WOSBibtex

Randomized, Open-Label, Study Comparing Efficacy and Safety of Lerodalcibep to Inclisiran in Patients with CVD or at High Risk for CVD Requiring Additional LDL-cholesterol Reduction

Ulrich Laufs, Manuela Licka,Emil Asprusten,Bertrand Cariou,Nicholas Jacobsen,Fernando Civeira Murillo, Jeffrey Vest,David Kallend,Evan Stein

Atherosclerosis (2024): 118406-118406

Cited0Views0Bibtex

Long Term Efficacy and Safety of Lerodalcibep in Patients with Atherosclerotic Cardiovascular Disease (Liberate-Cvd)

Dean Kereiakes,Nyda Fourie, Johannes Engelbrecht,Lesley Burgess, Jane Kerr, Zafir Yalim, Jeffrey Vest,David Kallend,Evan Stein

Atherosclerosis (2024): 118513-118513

Cited0Views0Bibtex

Efficacy and Safety of Lerodalcibep in Patients with or at High Risk of Cardiovascular Disease A Randomized Clinical Trial

Eric Q. Klug, Sara Llerena,Lesley J. Burgess,Nyda Fourie,Russell Scott, Jeff Vest,Kate Caldwell,David Kallend, Evan A. Stein

JAMA Cardiology（2024）

Cited0Views0WOSBibtex

Long-term Efficacy and Safety of Lerodalcibep in Heterozygous Familial Hypercholesterolaemia: the LIBerate-HeFH Trial

Frederick Raal,Nyda Fourie,Russell Scott,Dirk Blom, Matthys De Vries Basson,Meral Kayikcioglu,Kate Caldwell,David Kallend,Evan Stein

EUROPEAN HEART JOURNAL（2023）

Cited12Views0WOSBibtex

Inclisiran and Cardiovascular Events: a Patient-Level Analysis of Phase III Trials

Kausik K. Ray,Frederick J. Raal,David G. Kallend,Mark J. Jaros,Wolfgang Koenig,Lawrence A. Leiter,Ulf Landmesser,Gregory G. Schwartz,David Lawrence,Andrew Friedman,Lorena Garcia Conde,R. Scott Wright

EUROPEAN HEART JOURNAL（2023）

Cited96Views0WOSBibtex

The N-Acetylgalactosamine-conjugated Small Interfering RNA Inclisiran Can Be Coadministered Safely with Atorvastatin in Cynomolgus Monkeys Resulting in Additive Low-Density Lipoprotein Cholesterol Reductions

Dario Lehoux,David Kallend,Peter L. J. Wijngaard,Alan P. Brown,Brad Zerler

PHARMACOLOGY RESEARCH & PERSPECTIVES（2023）

Cited1Views0WOSBibtex

Randomized, Open-Label, Cross-Over, Phase-3 Study to Evaluate Efficacy and Safety of LIB003 Compared with Evolocumab in Homozygous Familial Hypercholesterolaemia Patients on Stable Lipid-Lowering Therapy (Liberate-Hofh)

F. Raal, V. Mehta,M. Kayikcioglu,D. Blom, P. Gupta, C. Daniels, J. Vest, K. Caldwell,E. M. Bahassi,D. Kallend, E. Stein

ATHEROSCLEROSIS（2023）

Cited0Views0Bibtex

Pharmacokinetics and Pharmacodynamics of Inclisiran, a Small Interfering RNA Therapy, in Patients with Hepatic Impairment

David Kallend,Robert Stoekenbroek,YanLing He,Patrick F. Smith,Peter Wijngaard

Journal of clinical lipidology（2022）

Cited44Views0WOSBibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn